Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cataractogenic Potential of Quetiapine vs Risperidone in Schizophrenia
NCT00206102Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2003
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of quetiapine (extended-release tablet, brand name: Bipresso) in schizophrenia, schizoaffective disorder, sponsored by AstraZeneca. Started Sep 2003; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00206102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206102.